Bruker Daltonics Announces that Certain Stockholders Sold Two Million Shares in a Block Trade.

Business/Technology Editors

BILLERICA, Mass.--(BUSINESS WIRE)--Nov. 8, 2001

Bruker Daltonics Inc. (NASDAQ:BDAL) today reported that following the close of trading on November 7, 2001, four members of the Laukien Family each have sold 500,000 shares of Bruker Daltonics, or an aggregate of 2.0 million shares, in a block trade transaction handled by UBS Warburg.

For each selling shareholder, the number of shares sold represents approximately 5.5% of such shareholders ownership of Bruker Daltonics shares. As a result of this transaction, the public float of the Company has increased from approximately 9.4 million shares, or 17%, to approximately 11.4 million shares, or 20%, of the issued stock. Frank Laukien, the Company's President and CEO, did not sell any shares.

The Company's CFO, John Hulburt, said: "This sale was in response to recent increased trading activity, and serves to increase the Company's public float and offer greater liquidity for its investors. The members of the Laukien family remain committed to Bruker Daltonics, but in the long run are willing to see the public ownership and public float of the Company increase."

ABOUT BRUKER DALTONICS

Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information about Bruker Daltonics, please visit www.bdal.com.

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation to update the information contained herein.